Shares of Pernix Therapeutics climbed more than 9% at one point Friday after the drug maker said it won U.S. Food and Drug Administration approval to market a new migraine treatment designed for teenage patients and older individuals. The treatment, known as Treximent, combines sumatriptan and naproxen sodium. Pernix estimates one in five teenagers suffers from migraines and haven't had the same options as adults for treating the malady. In recent action, shares were up 6% to $6.86.
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below